Trousdale M D, Goldstein L, Stebbing N, Peters A C, Schanzlin D J, Robin J B
Invest Ophthalmol Vis Sci. 1985 Sep;26(9):1244-51.
Complete gene synthesis methods have been used to construct analogs of human interferons (IFNs): these include a consensus of the known human IFN-alpha S, designated IFN-alpha Con1 and a variant of human IFN-gamma, designated IFN-gamma 4A. These interferons, in purified form, were used topically against herpes simplex virus type 1 (HSV-1) induced ocular keratitis in rabbits. Eyes pretreated with IFN-alpha Con1 had decreased signs of infection and a lower incidence of HSV-1 positive trigeminal ganglia (3 of 14 positive) compared to the placebo treated (10 of 14 positive). IFN-alpha Con1 was as effective as natural IFN-alpha subtypes on a units basis, despite the very high specific activity of this analog. IFN-gamma 4A used under similar conditions do not result in beneficial effects with treatments beginning 24 or 48 hr before or 4 hr after virus inoculation. Rabbits with confirmed latent HSV infection were treated topically with IFN-alpha Con1 (10(6) units per eye each day) either before or before and after attempts to intentionally reactivate the infection by bilateral iontophoresis of 6-hydroxydopamine plus topical epinephrine treatment of the corneas. These IFN-alpha Con1 treatment regimens along with intentional reactivation during latency did not: (1) lessen the frequency of inducible ocular shedding episodes; (2) alter the mean time of 3-5 days between attempts to reactive latent infection and the appearance of HSV in tears; or (3) significantly change the incidence of HSV-positive trigeminal ganglia (83-100% HSV positive).
全基因合成方法已被用于构建人干扰素(IFN)类似物:其中包括已知人IFN-αS的一种共识序列,命名为IFN-αCon1,以及人IFN-γ的一种变体,命名为IFN-γ4A。这些纯化形式的干扰素被局部用于治疗兔单纯疱疹病毒1型(HSV-1)诱导的眼部角膜炎。与安慰剂治疗组(14只中有10只为阳性)相比,用IFN-αCon1预处理的眼睛感染迹象减少,HSV-1阳性三叉神经节的发生率较低(14只中有3只为阳性)。尽管这种类似物的比活性非常高,但按单位计算,IFN-αCon1与天然IFN-α亚型的效果相同。在病毒接种前24或48小时或接种后4小时开始治疗的类似条件下使用IFN-γ4A,未产生有益效果。对确诊为潜伏性HSV感染的兔子,在通过双侧离子导入6-羟基多巴胺加角膜局部肾上腺素治疗试图有意重新激活感染之前或之后,局部用IFN-αCon1(每只眼每天10^6单位)治疗。这些IFN-αCon1治疗方案以及潜伏期的有意重新激活并未:(1)减少可诱导的眼部排毒发作频率;(2)改变在试图重新激活潜伏感染与泪液中出现HSV之间3至5天的平均时间;或(3)显著改变HSV阳性三叉神经节的发生率(83%-100%为HSV阳性)。